Recent advances in therapy for gastrointestinal stromal tumors
β Scribed by Robert G. Maki
- Book ID
- 107546510
- Publisher
- Current Science Inc.
- Year
- 2007
- Tongue
- English
- Weight
- 273 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1523-3790
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Progression on firstβline therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinibβresistant GIST include agents that target KIT/PDGFR
## Abstract The development of imitinab has led to a revolution in the management of gastrointestinal stromal tumors (GIST), but surgical resection remains the cornerstone of treatment for patients with localized disease. The principles to surgical treatment of GIST include careful handling of tiss